Glibenclamide antagonizes adenosine A1 receptor-mediated cardioprotection in stunned canine myocardium

Z Yao1, G J Gross

  • 1Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226.

Circulation
|July 1, 1993
PubMed
Abstract

Insights

Stimulating adenosine A1 receptors protects the heart from stunning caused by repeated blood flow blockages. This protective effect may involve ATP-dependent K channels (KATP), suggesting a potential therapeutic target for ischemic heart conditions.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Myocardial stunning is a post-ischemic dysfunction.
  • Adenosine receptors play a role in cardiac function during ischemia.
  • The specific adenosine receptor subtype and its interaction with KATP channels in stunning remain unclear.

Purpose of the Study:

  • To investigate the role of adenosine in myocardial stunning following repetitive coronary artery occlusions.
  • To identify the specific adenosine receptor subtype (A1 or A2) involved.
  • To examine the interaction between adenosine A1 receptors and ATP-dependent K channels (KATP).

Main Methods:

  • Studies were conducted in anesthetized dogs subjected to repetitive coronary artery occlusions and reperfusions.
  • Regional cardiac function was assessed using sonomicrometry.
  • Selective adenosine A1 receptor agonist (CPA) and antagonist (DPCPX), A2 receptor agonist (CGS 21680), and KATP channel blocker (glibenclamide) were administered.

Main Results:

  • CPA administration improved cardiac function recovery, while DPCPX worsened it.
  • Adenosine A2 receptor agonist CGS 21680 had no significant effect.
  • Glibenclamide abolished the protective effect of CPA, indicating involvement of KATP channels.

Conclusions:

  • Myocardial adenosine A1 receptor stimulation, especially early in ischemia, offers cardioprotection against repetitive occlusions.
  • This cardioprotection appears to be partly mediated through glibenclamide-sensitive mechanisms, likely involving KATP channel opening.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...